Literature DB >> 25278388

The rise in Clostridium difficile infection incidence among hospitalized adults in the United States: 2001-2010.

Kelly R Reveles1, Grace C Lee2, Natalie K Boyd2, Christopher R Frei2.   

Abstract

BACKGROUND: Clostridium difficile infection (CDI) incidence is a growing concern. This study provides national estimates of CDI over 10 years and identifies trends in mortality and hospital length of stay (LOS) among hospitalized adults with CDI.
METHODS: We conducted a retrospective analysis of the US National Hospital Discharge Surveys from 2001-2010. Eligible cases included adults aged ≥ 18 years discharged from a hospital with an ICD-9-CM diagnosis code for CDI (008.45). Data weights were used to derive national estimates. CDI incidence rates were depicted as CDI discharges per 1,000 total adult discharges.
RESULTS: These data represent 2.2 million adult hospital discharges for CDI over the study period. CDI incidence increased from 4.5 CDI discharges per 1,000 total adult discharges in 2001 to 8.2 CDI discharges per 1,000 total adult discharges in 2010. The overall in-hospital mortality rate was 7.1% for the study period. Mortality increased slightly over the study period, from 6.6% in 2001 to 7.2% in 2010. Median hospital LOS was 8 days (interquartile range, 4-14 days), and remained stable over the study period.
CONCLUSIONS: The incidence of CDI among hospitalized adults in the United States nearly doubled from 2001-2010. Furthermore, there is little evidence of improvement in patient mortality or hospital LOS.
Copyright © 2014 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Epidemiology; Length of stay; Mortality

Mesh:

Year:  2014        PMID: 25278388     DOI: 10.1016/j.ajic.2014.06.011

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  41 in total

Review 1.  Primary Prevention of Clostridium difficile-Associated Diarrhea: Current Controversies and Future Tools.

Authors:  Zachary A Rubin; Elise M Martin; Paul Allyn
Journal:  Curr Infect Dis Rep       Date:  2018-06-29       Impact factor: 3.725

2.  Comparison of Outcomes Between Total Abdominal and Partial Colectomy for the Management of Severe, Complicated Clostridium Difficile Infection.

Authors:  David Peprah; Alexander S Chiu; Raymond A Jean; Kevin Y Pei
Journal:  J Am Coll Surg       Date:  2018-12-18       Impact factor: 6.113

3.  Age and gender differences in Clostridium difficile-related hospitalization trends in Madrid (Spain) over a 12-year period.

Authors:  M D Esteban-Vasallo; S Naval Pellicer; M F Domínguez-Berjón; M Cantero Caballero; Á Asensio; G Saravia; J Astray-Mochales
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-04-07       Impact factor: 3.267

4.  Impact of Oral Fidaxomicin Administration on the Intestinal Microbiota and Susceptibility to Clostridium difficile Colonization in Mice.

Authors:  N J Ajami; J L Cope; M C Wong; J F Petrosino; L Chesnel
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

Review 5.  Clostridium difficile infection.

Authors:  Wiep Klaas Smits; Dena Lyras; D Borden Lacy; Mark H Wilcox; Ed J Kuijper
Journal:  Nat Rev Dis Primers       Date:  2016-04-07       Impact factor: 52.329

6.  Observational study of chemotherapy-induced Clostridium difficile infection in patients with lung cancer.

Authors:  Yukihiro Toi; Shunichi Sugawara; Takao Kobayashi; Keisuke Terayama; Yoshihiro Honda
Journal:  Int J Clin Oncol       Date:  2018-06-06       Impact factor: 3.402

7.  Safety, Tolerability, Systemic Exposure, and Metabolism of CRS3123, a Methionyl-tRNA Synthetase Inhibitor Developed for Treatment of Clostridium difficile, in a Phase 1 Study.

Authors:  Seema U Nayak; J McLeod Griffiss; Jeffrey Blumer; Mary Ann O'Riordan; Wesley Gray; Robin McKenzie; Robert A Jurao; Amanda T An; Melissa Le; Stacie J Bell; Urs A Ochsner; Thale C Jarvis; Nebojsa Janjic; Jonathan M Zenilman
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

8.  Post-hospitalization Treatment Regimen and Readmission for C. difficile Colitis in Medicare Beneficiaries.

Authors:  Charles M Psoinos; Courtney E Collins; M Didem Ayturk; Frederick A Anderson; Heena P Santry
Journal:  World J Surg       Date:  2018-01       Impact factor: 3.352

9.  In the Endemic Setting, Clostridium difficile Ribotype 027 Is Virulent But Not Hypervirulent.

Authors:  Samuel L Aitken; M Jahangir Alam; Mohammed Khaleduzzaman; Mohammed Khaleduzzuman; Seth T Walk; William L Musick; Vy P Pham; Jennifer L Christensen; Robert L Atmar; Yang Xie; Kevin W Garey
Journal:  Infect Control Hosp Epidemiol       Date:  2015-08-20       Impact factor: 3.254

10.  The Importance of Colonization with Clostridium difficile on Infection and Transmission.

Authors:  Daniel J Morgan; Surbhi Leekha; Lindsay Croft; Carey-Ann D Burnham; J Kristie Johnson; Lisa Pineles; Anthony D Harris; Erik R Dubberke
Journal:  Curr Infect Dis Rep       Date:  2015-09       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.